CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

<p>Abstract</p> <p>Background</p> <p>Various biomarkers for prediction of distant metastasis in lymph-node negative breast cancer have been described; however, predictive biomarkers for patients with lymph-node positive (LNP) disease in the context of distinct systemic...

Full description

Bibliographic Details
Main Authors: Eppenberger-Castori Serenella, Schmitt Manfred, Harbeck Nadia, Lewin Jörn, Fassbender Anne, Dietrich Jörn, Krispin Manuel, Dietrich Dimo, Vuaroqueaux Vincent, Spyratos Frédérique, Foekens John A, Lesche Ralf, Martens John WM
Format: Article
Language:English
Published: BMC 2010-06-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/247

Internet

http://www.biomedcentral.com/1471-2407/10/247

Similar Items